China Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma approved for initiation by YAOZHUANGKANG-B (02617.HK).

Smart Financial News APP, Sino Biopharma-B (02617.HK) announced that the company's product TT-01488 tablet combined with anti-CD20 monoclonal antibody therapy regimen for the treatment of mantle cell lymphoma (MCL) phase II clinical trial has been approved by the National Medical Products Administration (NMPA) on July 1, 2026.